The Family Impact of Atopic Dermatitis in the Pediatric Population: Results from an International Cross-sectional Study - 22/06/22
, Jonathan I. Silverberg, MD, PhD, MPH 2, Abhijit Gadkari, PhD 3, Eric L. Simpson, MD 4, Stephan Weidinger, MD 5, Paola Mina-Osorio, MD, PhD 3, Ana B. Rossi, MD, CMD 6, Lysel Brignoli, MS 7, Tarek Mnif, PharmD 7, Isabelle Guillemin, PhD 8, Miriam C. Fenton, PhD, MPH 6, Marine Pellan, MS 7, Puneet Mahajan, PhD 9, Dimittri Delevry, PharmD 3, Ashish Bansal, MD, MBA 3, Laurent Eckert, PhD 8Abstract |
Objective |
To evaluate the impact of atopic dermatitis on families of pediatric patients.
Study design |
This cross-sectional, web-based survey of children/adolescents (6 months to <18 years old) with atopic dermatitis and their parents and caregivers was conducted in 18 countries encompassing North America, Latin America, Europe, Middle East/Eurasia, and East Asia. Children and adolescents with atopic dermatitis and their parents and caregivers were identified by the International Study of Asthma and Allergies in Childhood criteria and ever being told by a physician that they had “eczema”. Atopic dermatitis severity was assessed using the Patient-Oriented Eczema Measure and the Patient Global Assessment. Atopic dermatitis impact on families’ lives was evaluated using the Dermatitis Family Impact questionnaire and stand-alone questions on hours of atopic dermatitis-related care (past week) and missed work days (past 4 weeks) owing to their child’s atopic dermatitis.
Results |
A total of 7465 pairs of pediatric participants with atopic dermatitis and their parents or caregivers were surveyed. Across age groups, the Dermatitis Family Impact questionnaire total score for all regions ranged from 7.1 to 8.6, 13.2 to 14.9, and 17.0 to 17.2 for Patient-Oriented Eczema Measure mild, moderate, and severe atopic dermatitis, respectively. Subscale scores showed that greater atopic dermatitis severity had a greater impact on all family life domains, including sleep and tiredness. No specific patterns or trends were observed across age groups. Time spent on childcare and missed work days increased with atopic dermatitis severity.
Conclusions |
Across pediatric age groups and geographic regions, greater atopic dermatitis severity was associated with a greater negative impact on physical, emotional, social, and economic components of family life.
Le texte complet de cet article est disponible en PDF.Keywords : atopic dermatitis, family burden, parents/caregivers, dermatitis family impact questionnaire
Abbreviations : DFI, EPI-CARE, ISAAC, POEM, PtGA
Plan
| Funded by Sanofi and Regeneron Pharmaceuticals. S.B. has received research grants from Pierre Fabre Laboratory and Fondation pour la dermatite atopique; personal fees from Bioderma, Laboratoire La Roche Posay, Sanofi-Genzyme, Novalac, and Ferring; and nonfinancial support from AbbVie, Novartis, and Janssen. J.S. has acted as a consultant for and/or received grants/honoraria from AbbVie, AnaptysBio, Asana Biosciences, LLC, Eli Lilly and Company, Galderma Research & Development, LLC, GlaxoSmithKline, Glenmark Generics Inc., Kiniksa Pharmaceuticals, Ltd., Leo Pharma Inc., Medimmune, Menlo Therapeutics, Pfizer Inc., PuriCore, Inc., Regeneron, and Sanofi. E.S. has received grants/research support from Amgen, Celgene, Chugai, Galderma, Genentech, Medimmune, Sanofi/Regeneron Pharmaceuticals, Tioga, Vanda, and Lilly, and is a consultant for Anacor, Celgene, Galderma, Genentech, Medicis, Sanofi/Regeneron Pharmaceuticals, and Merck. S.W. is co-principal investigator of the German Atopic Dermatitis Registry TREATgermany, and has received institutional research grants from Novartis, Pfizer, L’Oreal, and LEO; has performed consultancies for Sanofi-Genzyme, Regeneron, LEO Pharma, Incyte, and Novartis; has lectured at educational events sponsored by Sanofi-Genzyme, Regeneron, LEO Pharma, AbbVie, and Galderma; and is involved in performing clinical trials with many pharmaceutical industries that manufacture drugs used for the treatment of psoriasis and atopic eczema. L.B., T.M., and M.P. are employees of Kantar Health Division, who received funding from Sanofi to conduct the study. A.R. and L.E. are employees of and stockholders in Sanofi. P.M. and I.G. were employees of Sanofi at the time the study was conducted. D.D. and A.B. are employees of and stockholders in Regeneron Pharmaceuticals Inc. P.O. was an employee of and stockholder in Regeneron Pharmaceuticals Inc at the time the study was conducted; she is a current employee of Aurinia Pharmaceuticals. A.G. was an employee of and stockholder in Regeneron Pharmaceuticals at the time of the study; he is a current employee of Boehringer Ingelheim Corporation. M.F. was an employee of Sanofi at the time of study and is currently employed at Syneos Health. |
Vol 246
P. 220 - juillet 2022 Retour au numéro
Article précédent
- Measles Experience, Practice, and Knowledge by Pediatricians in the Context of Resurgent US Outbreaks
- Jessica R. Cataldi, Sean T. O'Leary, Brenda L. Beaty, Laura P. Hurley, Lori A. Crane, Michaela Brtnikova, Carol Gorman, Allison Kempe
- 50 Years Ago in The Journal of Pediatrics : How Sweet It Is: Hyperglycemia in Infants on Parenteral Nutrition
- Bridget Whitehead, Valeria Cohran
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?